Photoresponsive prodrug‐dye nanoassembly for in‐situ monitorable cancer therapy

Long, Kaiqi; Wang, Yifan; Lv, Wen; Yang, Yang; Xu, Shuting; Zhan, Changyou; Wang, Weiping

doi:10.1002/btm2.10311

Cited by 13 publications

(7 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, other recent articles are focusing on the transportation potential of nanomedicines as drug-carrier materials [ 26 ]. Our research shows that fullerenol as a drug carrier has an obvious repairing effect on lead-poisoning, which exhibits good therapeutic potential.…”

Section: Discussionmentioning

confidence: 99%

Long-term maintenance of synaptic plasticity by Fullerenol Ameliorates lead-induced-impaired learning and memory in vivo

et al. 2022

View full text Add to dashboard Cite

Fullerenol, a functional and water-soluble fullerene derivative, plays an important role in antioxidant, antitumor and antivirus, implying its enormous potential in biomedical applications. However, the in vivo performance of fullerenol remains largely unclear. We aimed to investigate the effect of fullerenol (i.p., 5 mg/kg) on the impaired hippocampus in a rat model of lead exposure. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF–MS) is a kind of newly developed soft-ionization mass spectrometry technology. In the present study, an innovative strategy for biological distribution analysis using MALDI-TOF–MS confirmed that fullerenol could across the blood–brain barrier and accumulate in the brain. Results from behavioral tests showed that a low dose of fullerenol could improve the impaired learning and memory induced by lead. Furthermore, electrophysiology examinations indicated that this potential repair effect of fullerenol was mainly due to the long-term changes in hippocampal synaptic plasticity, with enhancement lasting for more than 2–3 h. In addition, morphological observations and biochemistry analyses manifested that the long-term change in synaptic efficacy was accompanied by some structural alteration in synaptic connection. Our study demonstrates the therapeutic feature of fullerenol will be beneficial to the discovery and development as a new drug and lays a solid foundation for further biomedical applications of nanomedicines.

show abstract

Section: Discussionmentioning

confidence: 99%

Long-term maintenance of synaptic plasticity by Fullerenol Ameliorates lead-induced-impaired learning and memory in vivo

et al. 2022

View full text Add to dashboard Cite

show abstract

“…[ 38 ] The study validated the photo‐enhanced drug accumulation as a promising option for systemic treatment of eye diseases. Considering that long‐wavelength light (e.g., red or near‐infrared (NIR) light) could be an appropriate irradiation source due to its deep tissue penetration and reduced risks of phototoxicity to the eye, [ 41 , 42 , 43 ] we have been further working on the development of ophthalmic nanosystems that can respond to red or NIR light. Conventional red/NIR light‐responsive systems mainly rely on the two‐photon excitation mechanism or photon upconversion process, where lasers equipped with high‐power sources are required.…”

Section: Discussionmentioning

confidence: 99%

Red Light‐Triggered Anti‐Angiogenic and Photodynamic Combination Therapy of Age‐Related Macular Degeneration

Xu,

Cui,

Long

et al. 2023

Advanced Science

Self Cite

View full text Add to dashboard Cite

Choroidal neovascularization (CNV) is the key pathological event of wet age‐related macular degeneration (wAMD) leading to irreversible vision loss. Currently, anti‐angiogenic therapy with anti‐vascular endothelial growth factor (VEGF) agents has become the standard treatment for wAMD, while it is still subject to several limitations, including the safety concerns of monthly intravitreal administration and insufficient efficacy for neovascular occlusion. Combined therapy with photodynamic therapy (PDT) and anti‐angiogenic agents has emerged as a novel treatment paradigm. Herein, a novel and less‐invasive approach is reported to achieve anti‐angiogenic and photodynamic combination therapy of wAMD by intravenous administration of a photoactivatable nanosystem (Di‐DAS‐VER NPs). The nanosystem is self‐assembled by reactive oxygen species (ROS)‐sensitive dasatinib (DAS) prodrug and photosensitizer verteporfin (VER). After red‐light irradiation to the diseased eyes, intraocular release of anti‐angiogenic DAS is observed, together with selective neo‐vessels occlusion by VER‐generated ROS. Notably, Di‐DAS‐VER NPs demonstrates promising therapeutic efficacy against CNV with minimized systemic toxicity. The study enables an efficient intravenous wAMD therapy by integrating a photoactivation process with combinational therapeutics into one simple nanosystem.

show abstract

“…Additionally, both prodrugs and photosensitizer molecules have poor solubility in aqueous media, which has hindered the biomedical application of single-photon upconversion-type photolysis strategies. [39] The use of amphiphilic block copolymers such as poly(lactic acid)poly(ethylene glycol) (PLA5000À mPEG3400) to encapsulate prodrugs and photosensitizers in polymer micelles helps improve water solubility. By encapsulating prodrugs and photosensitizers within micelles, they are partially protected from oxygen attack during the single-photon upconversion-type photolysis process.…”

Section: Triplet-triplet Energy Transfermentioning

confidence: 99%

“…Oxygen can also directly quench the triplet excited state of prodrug molecules, reducing photolysis efficiency. Additionally, both prodrugs and photosensitizer molecules have poor solubility in aqueous media, which has hindered the biomedical application of single‐photon upconversion‐type photolysis strategies [39] . The use of amphiphilic block copolymers such as poly(lactic acid)‐poly(ethylene glycol) (PLA5000−mPEG3400) to encapsulate prodrugs and photosensitizers in polymer micelles helps improve water solubility.…”

Section: Photocatalytic Release Of Drugmentioning

confidence: 99%

Photocatalytic Release of Bioactive Agents for Therapeutic Applications

Zheng,

He,

Chen

et al. 2023

ChemCatChem

View full text Add to dashboard Cite

Photocatalysis has recently emerged as a unique and robust tool for tackling challenges in research areas spacing from chemical processes (synthesis, energy storage, et al.) to biomedical applications (phototherapy, drug delivery, et al.). In particular, the use of a photocatalyst to control and/or trigger the release of bioactive agents in biological systems has attracted increasing attention because the non‐invasive characteristics and precise spatiotemporal control associated with light offers a unique solution to challenges in conventional local delivery of bioactive agents. This review summarizes the design principles of novel photocatalysts and photocatalytic processes that are suitable for long‐wavelength light activation, as well as the recent development in photocatalytic release of bioagents with a focus on gasotransmitters, drugs, and reactive oxygen species (ROS).

show abstract

Photoresponsive prodrug‐dye nanoassembly for in‐situ monitorable cancer therapy

Cited by 13 publications

References 58 publications

Long-term maintenance of synaptic plasticity by Fullerenol Ameliorates lead-induced-impaired learning and memory in vivo

Long-term maintenance of synaptic plasticity by Fullerenol Ameliorates lead-induced-impaired learning and memory in vivo

Red Light‐Triggered Anti‐Angiogenic and Photodynamic Combination Therapy of Age‐Related Macular Degeneration

Photocatalytic Release of Bioactive Agents for Therapeutic Applications

Contact Info

Product

Resources

About